Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma

Lung cancer is the leading cause of cancer-related mortality worldwide [1]. With the popularity of low-dose computed tomography (CT) screening, more and more early-stage lung cancers were being diagnosed. Flores et al. found a stage shift from later to earlier stage disease among people with lung cancer over the last decade. From 2006 to 2016, stage I-II lung cancer diagnoses increased from 26.5  % to 31.2 %, and stage III-IV diagnoses decreased from 70.8 % to 66.1 % [2]. The majority of patients diagnosed with low-dose CT were in the earlier stage.

Source: Lung Cancer - April 11, 2024 Category: Cancer & Oncology Authors: Yueh-Feng Lu, Ya-Hsuan Chang, Yi-Ju Chen, Min-Shu Hsieh, Mong-Wei Lin, Hsao-Hsun Hsu, Chia-Li Han, Yu-Ju Chen, Sung-Liang Yu, Jin-Shing Chen, Hsuan-Yu Chen Source Type: research